Change has been the one constant in nuclear medicine from the beginning, with the steady arrival of new radiopharmaceuticals, new technologies and an evolving regulatory environment.
Today, as nuclear medicine expands rapidly beyond diagnostics and into novel therapies personalized for individual patients, there is greater complexity and an even faster rate of change.
Theranostics and precision healthcare hold much promise for improving patients’ lives, but nuclear medicine departments face challenges in adopting new theranostics and ensuring patient access. In this complex, rapidly changing industry, the experts at Cardinal HealthTM Nuclear & Precision Health Solutions have been providing trusted advice and guidance for more than 40 years, helping nuclear medicine departments prepare for and embrace the future. For example:
- We established the first-ever commercial centralized nuclear pharmacy in 1972;
- We created the first nationwide radiopharmacy network in 1982;
- We opened the first commercial positron emission tomography (PET) cyclotron in 1992;
- We completed our purchase of LYMPHOSEEK® in 2017.